NCT05287438 is a NA clinical trial of Next-Generation DNA Sequencing in Penile Implantation, sponsored by MicroGenDX.

Who is sponsoring NCT05287438?

NCT05287438 is sponsored by MicroGenDX.

What drugs are being tested in NCT05287438?

Interventions in NCT05287438: Next-Generation DNA Sequencing, Standard Culture.

What condition does NCT05287438 study?

NCT05287438 studies Penile Implantation, Infections.

Is NCT05287438 still recruiting?

NCT05287438 is currently status unknown. Last updated 18 March 2022.

Last reviewed 2022-03-18 · How we verify

NCT05287438

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Next Generation Sequencing Versus Traditional Cultures for Clinically Infected Penile Implants: Impact of Culture Identification on Outcomes

Status unknown NA Last updated 18 March 2022

What this trial tests

NA trial testing Next-Generation DNA Sequencing in Penile Implantation in 40 participants. Status unknown.

Timeline

27 October 2021

Primary endpoint
31 October 2023

31 October 2024

Quick facts

Lead sponsor	MicroGenDX
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	27 October 2021
Primary completion	31 October 2023
Estimated completion	31 October 2024
Sites	3 locations across United States

Drugs / interventions tested

Next-Generation DNA Sequencing
Standard Culture

Conditions studied

Penile Implantation — all drugs for Penile Implantation →
Infections — all drugs for Infections →

Sponsor

MicroGenDX

Who can join

Adults 18 to 80, male only, with Penile Implantation or Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized prospective study to evaluate next generation sequencing (NGS) and standard-of-care culture for clinically infected penile implants and to compare outcomes with identification of microbes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other MicroGenDX trials

Trials by the same sponsor.

NCT05276466 — Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05287438 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MicroGenDX
Last refreshed: 18 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05287438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing